Wezlana™
Understanding Wezlana®
Wezlana® (ustekinumab-auub) is a biosimilar to Stelara® (ustekinumab), developed by Amgen. It is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), cytokines involved in inflammatory and immune responses. By inhibiting these cytokines, Wezlana® helps reduce inflammation associated with certain autoimmune conditions.
How Wezlana® Works:
- Binds to the p40 protein subunit shared by IL-12 and IL-23, preventing their interaction with cell surface receptors.
- Inhibits the activation of T-helper cells, reducing the release of pro-inflammatory cytokines.
- Decreases inflammation and immune-mediated tissue damage in affected conditions.
FDA Approval:
- October 31, 2023 – Approved as an interchangeable biosimilar to Stelara® for:
- Moderate to severe plaque psoriasis in adults and pediatric patients aged 6 years and older.
- Active psoriatic arthritis in adults and pediatric patients aged 6 years and older.
- Moderately to severely active Crohn’s disease in adults.
- Moderately to severely active ulcerative colitis in adults
For more information, please visit the Wezlana® patient website. Speak with your healthcare provider to determine if Wezlana® is the right treatment option for you.
Referral Form: |
MANUFACTURER: Amgen Inc. |
CLASS: Monoclonal Antibody (mAb)
Interleukin Inhibitor - Specifically: IL-12 and IL-23 antagonist |
|
PRESCRIBED BY:
|
|
HOW ADMINISTERED: IV Infusion or Subcutaneous Injection, depending on condition and point in treatment |
|
FREQUENCY: Plaque Psoriasis and Psoriatic Arthritis: Initial doses week zero and week four, then every 12 weeks Crohn’s Disease (Adults) and Ulcerative Colitis: Loading dose, then every eight weeks.
|
Length of infusion: About 1 hour |
FOR MORE INFORMATION: |
Related drugs
